Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico
The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. Material and Methods. A decision tree was developed in preterm groups [<29 and 29-32...
Uloženo v:
| Vydáno v: | Salud Pública de México |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Instituto Nacional de Salud Pública
2012
|
| Témata: | |
| On-line přístup: | https://www.redalyc.org/articulo.oa?id=10623032007 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|